Login to Your Account



Samsung wins first U.S. biosimilar approval as FDA clears Renflexis

By Haky Moon
Staff Writer

Monday, April 24, 2017

HONG KONG – Samsung Bioepis Co. Ltd.'s biosimilar Renflexis will be the first product of the conglomerate's biologics arm to be marketed in the U.S. and only the second infliximab biosimilar in the market after Pfizer Inc.'s Inflectra.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription